Dopaminergic Therapy for Frontotemporal Dementia Patients: an Interventional, Multi-site, Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of RTG Treatment in Patients with Behavioral FTD
Latest Information Update: 24 Oct 2024
Price :
$35 *
At a glance
- Drugs Rotigotine (Primary)
- Indications Frontotemporal dementia
- Focus Therapeutic Use
- 22 Oct 2024 Status changed from active, no longer recruiting to completed.
- 07 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2022 Planned primary completion date changed from 30 Sep 2023 to 30 Dec 2023.